Prescient Therapeutics Limited

ASX (AUD): Prescient Therapeutics Limited (PTX)

Last Price

0.048

Today's Change

+0.007 (17.07%)

Day's Change

0.048 - 0.063

Trading Volume

11,514,770

Overview

Market Cap

38 Million

Shares Outstanding

805 Million

Avg Volume

421,056

Avg Price (50 Days)

0.04

Avg Price (200 Days)

0.04

PE Ratio

-4.80

EPS

-0.01

Earnings Announcement

21-Feb-2025

Previous Close

0.04

Open

0.05

Day's Range

0.048 - 0.063

Year Range

0.037 - 0.068

Trading Volume

11,514,770

Price Change Highlight

1 Day Change

17.07%

5 Day Change

14.29%

1 Month Change

29.73%

3 Month Change

23.08%

6 Month Change

20.00%

Ytd Change

-29.41%

1 Year Change

-26.15%

3 Year Change

-78.67%

5 Year Change

-36.84%

10 Year Change

-60.12%

Max Change

-99.98%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of various cancers in Australia. Its lead drug candidate is PTX-200, which is in Phase 2a clinical trial for HER2-negative breast cancer, Phase IB/2 clinical trial in relapsed and refractory AML, and Phase 1b in recurrent or persistent platinum-resistant ovarian cancer; and PTX-100, a RhoA inhibitor, for hematological and solid malignancies that focuses on cancers with Ras and RhoA mutations. It has a strategic collaboration with The University of Texas MD Anderson Cancer Center to develop blood cancer binder for OmniCAR. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. Prescient Therapeutics Limited was incorporated in 1986 and is based in Melbourne, Australia.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment